Apogee Therapeutics (APGE) Free Cash Flow (2022 - 2026)
Apogee Therapeutics (APGE) reported Free Cash Flow of -$55.6 million for Q1 2026, down 14.09% year-over-year from -$64.7 million in Q1 2025, and up 11.39% on a QoQ basis from -$62.7 million in Q4 2025.
Apogee Therapeutics (APGE) has 5 years of Free Cash Flow data on file, last reported at -$55.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 14.09% year-over-year to -$55.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 26.67% YoY) and the FY2025 annual result came in at -$232.6 million, down 34.97% from the prior year.
- Free Cash Flow rose to -$55.6 million in Q1 2026 per APGE's latest filing, from -$62.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$9.2 million in Q4 2022 and bottomed at -$67.7 million in Q4 2024.
- The 5-year median for Free Cash Flow is -$37.6 million (2024), against an average of -$38.9 million.
- The widest annual swing landed in 2023, when Free Cash Flow sank 223.8%; it then rose 7.39% in 2025.
- Tracing APGE's Free Cash Flow over 5 years: stood at -$9.2 million in 2022, then slumped by 223.8% to -$29.8 million in 2023, then plunged by 127.58% to -$67.7 million in 2024, then grew by 7.39% to -$62.7 million in 2025, then grew by 11.39% to -$55.6 million in 2026.
- Per Business Quant, the three latest APGE Free Cash Flow figures stand at -$55.6 million (Q1 2026), -$62.7 million (Q4 2025), and -$54.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -55.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.57 Mn |
| Mar 31, 2026 | -55.57 Mn |
| Dec 31, 2025 | -62.71 Mn |
| Dec 31, 2025 | -62.71 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Sep 30, 2025 | -54.29 Mn |
| Jun 30, 2025 | -66.89 Mn |
| Jun 30, 2025 | -66.89 Mn |
| Mar 31, 2025 | -48.71 Mn |
| Mar 31, 2025 | -48.71 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Dec 31, 2024 | -67.71 Mn |
| Sep 30, 2024 | -43.28 Mn |
| Sep 30, 2024 | -43.28 Mn |
| Jun 30, 2024 | -29.35 Mn |
| Jun 30, 2024 | -29.35 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Mar 31, 2024 | -31.99 Mn |
| Dec 31, 2023 | -29.75 Mn |
| Dec 31, 2023 | -29.75 Mn |
| Sep 30, 2023 | -19.88 Mn |
| Sep 30, 2023 | -19.88 Mn |
| Jun 30, 2023 | -14.57 Mn |
| Jun 30, 2023 | -14.57 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Mar 31, 2023 | -10.56 Mn |
| Dec 31, 2022 | -9.19 Mn |
| Dec 31, 2022 | -9.19 Mn |